Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Descriptor ID |
D016159
|
MeSH Number(s) |
D12.776.260.820 D12.776.624.776.775 D12.776.660.825 D12.776.744.845
|
Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- Oncoprotein p53
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- TP53 Protein
- Cellular Tumor Antigen p53
- p53 Antigen
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1992 | 2 | 0 | 2 | 1993 | 2 | 0 | 2 | 1994 | 1 | 2 | 3 | 1995 | 3 | 3 | 6 | 1996 | 5 | 5 | 10 | 1997 | 2 | 3 | 5 | 1998 | 3 | 5 | 8 | 1999 | 1 | 1 | 2 | 2000 | 3 | 4 | 7 | 2001 | 4 | 2 | 6 | 2002 | 9 | 9 | 18 | 2003 | 7 | 3 | 10 | 2004 | 8 | 3 | 11 | 2005 | 6 | 5 | 11 | 2006 | 8 | 5 | 13 | 2007 | 3 | 7 | 10 | 2008 | 4 | 10 | 14 | 2009 | 5 | 4 | 9 | 2010 | 9 | 5 | 14 | 2011 | 9 | 8 | 17 | 2012 | 5 | 7 | 12 | 2013 | 5 | 1 | 6 | 2014 | 7 | 6 | 13 | 2015 | 7 | 6 | 13 | 2016 | 6 | 4 | 10 | 2017 | 8 | 4 | 12 | 2018 | 5 | 6 | 11 | 2019 | 7 | 7 | 14 | 2020 | 5 | 3 | 8 | 2021 | 4 | 2 | 6 | 2022 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
-
Muralidharan A, Sotocinal SG, Yousefpour N, Akkurt N, Lima LV, Tansley S, Parisien M, Wang C, Austin JS, Ham B, Dutra GM, Rousseau P, Maldonado-Bouchard S, Clark T, Rosen SF, Majeed MR, Silva O, Nejade R, Li X, Donayre Pimentel S, Nielsen CS, Neely GG, Autexier C, Diatchenko L, Ribeiro-da-Silva A, Mogil JS. Long-term male-specific chronic pain via telomere- and p53-mediated spinal cord cellular senescence. J Clin Invest. 2022 04 15; 132(8).
-
Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022 Jul; 97(7):E232-E235.
-
Pollock NC, Ramroop JR, Hampel H, Troester MA, Conway K, Hu JJ, Freudenheim JL, Olopade OI, Huo D, Ziv E, Neuhausen SL, Stevens P, McElroy JP, Toland AE. Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Res Treat. 2022 Apr; 192(3):639-648.
-
Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS, Pytel P, Borys E, Klonoski JM, McCord M, Horbinski C, Brat D, Perry A, Solomon D, Eberhart C, Giannini C, Quezado M, Aldape K. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathol. 2022 03; 143(3):403-414.
-
Concepcion AR, Wagner LE, Zhu J, Tao AY, Yang J, Khodadadi-Jamayran A, Wang YH, Liu M, Rose RE, Jones DR, Coetzee WA, Yule DI, Feske S. The volume-regulated anion channel LRRC8C suppresses T cell function by regulating cyclic dinucleotide transport and STING-p53 signaling. Nat Immunol. 2022 02; 23(2):287-302.
-
Kostiou V, Hall MWJ, Jones PH, Hall BA. Simulations reveal that different responses to cell crowding determine the expansion of p53 and Notch mutant clones in squamous epithelia. J R Soc Interface. 2021 10; 18(183):20210607.
-
Paris EA, Bahr JM, Bitterman P, Basu S, Abramowicz JS, Barua A. Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer. PLoS One. 2021; 16(7):e0255007.
-
Erhunmwunsee L, Wing SE, Shen J, Hu H, Sosa E, Lopez LN, Raquel C, Sur M, Ibarra-Noriega P, Currey M, Lee J, Kim JY, Raz DJ, Amini A, Sampath S, Koczywas M, Massarelli E, West HL, Reckamp KL, Kittles RA, Salgia R, Seewaldt VL, Neuhausen SL, Gray SW. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505.
-
Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D'Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 11; 35(11):3245-3256.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|